Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this observational study is to follow all patients implanted with extravascular implantable cardioverter-defibrillators (EV-ICDs) in Belgium throughout the lifetime of the devices. The main goal of the study is to keep track of:
The BELIEVE registry (BELgian registry of Implanted EV-ICDs to Evaluate parameters and complications) is a multicenter, observational registry designed to gather real-world data on the use of extravascular implantable cardioverter-defibrillators (EV-ICDs) in Belgium. This new generation of ICD technology offers the potential advantages of both subcutaneous (S-ICD) and transvenous (TV-ICD) devices, with the lead placed under the sternum. This position enables pacing capabilities and more accurate arrhythmia detection while aiming to minimize lead-related complications seen in previous ICD systems.
Given the relatively recent introduction of EV-ICDs, it is essential to monitor their performance and clinical outcomes in routine clinical settings. While initial trials have demonstrated feasibility and safety, real-world data are crucial for understanding long-term efficacy, complication rates, therapy effectiveness, device longevity, and overall patient outcomes. The BELIEVE registry was therefore established to support this need, offering a structured framework to follow patients over time and improve clinical practice related to EV-ICDs.
The registry is both retrospective and prospective, non-randomized, and will include all patients in Belgium who undergo (or have undergone) an EV-ICD implantation-regardless of whether the procedure was successful. Participating centers will aim to enroll an initial cohort of 100 patients over a 4-year period, although the number of patients and study duration may be extended. The total planned study period is 15 years, with patients followed throughout the life of their device.
Inclusion criteria are broad: participants must be at least 18 years old, have had or be scheduled for an EV-ICD implantation (even if unsuccessful), and must provide informed consent. Patients who did not undergo any part of the implantation procedure are excluded.
Data will be collected at baseline, during the procedure, and during scheduled follow-up visits (at 1-3 months, 6 months, and then at least annually). Information will include demographic and clinical characteristics, medical history, device data, arrhythmia detection, therapy delivery, programming changes, complications, and patient-reported outcomes.
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Number of delivered therapies (ATP and shocks) | Total number of therapies delivered by the device, including antitachycardia pacing and shocks (Unit: count) | Lifetime of the device (up to 15 years) |
| Proportion of delivered therapies that were appropriate | Percentage of therapies delivered by the device that were adjudicated as appropriate (i.e., delivered for true ventricular arrhythmia). | Lifetime of the device (up to 15 years) |
| Proportion of delivered therapies that were successful | Percentage of therapies delivered by the device that successfully terminated the targeted ventricular arrhythmia. | Lifetime of the device (up to 15 years) |
| Tracking procedural and device-related complications | Tracking procedural and device-related complications during the lifetime of the device | Lifetime of the device (up to 15 years) |
| Measure | Description | Time Frame |
|---|---|---|
| Change in sensing amplitude over time | Change in device-recorded sensing amplitude (in mV) from implantation to follow-up visits. | Lifetime of the device (up to 15 years) |
| Change in pacing threshold over time |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
All patients who underwent or will undergo an EV-ICD implantation in Belgium, whether successful or not, can be included in this registry.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Emma Christiaen | Contact | +32 50 45 32 93 | SM-SJ-Cardiologie-Studies@azsintjan.be |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Change in pacing threshold (in Volt) measured during device follow-up from implantation to 15 years.
| Lifetime of the device (up to 15 years) |
| Change in lead impedance over time | Change in lead impedance (in Ohm) from implantation to 15 years of follow-up. | Lifetime of the device (up to 15 years) |
| Change in battery longevity estimates over time | Change in estimated battery longevity (in years) as reported by the device at each follow-up visit. | Lifetime of the device (up to 15 years) |
| Accuracy of arrhythmia detection by the device | Proportion of arrhythmia episodes correctly classified by the device (%) | Lifetime of the device (up to 15 years) |
| Summary of device reprogramming | Summary of every device reprogramming including reason for changes | Lifetime of the device (up to 15 years) |
| Number of participants with major adverse cardiac events (MACE) | Number of participants experiencing major adverse cardiac events, including cardiovascular death, hospitalization for heart failure, myocardial infarction, or stroke. | Lifetime of the device (up to 15 years) |
| Number of participants with device-related infections | Number of participants with infections requiring antibiotic treatment or device/system extraction. | Lifetime of the device (up to 15 years) |
| Number of participants reporting device-related complaints | Number of participants reporting device-related symptoms or complaints (e.g., inappropriate shocks, pain at device site). | Lifetime of the device (up to 15 years) |